Astellas Pharma Unspadr Stock Fundamentals
| YPHA Stock | EUR 9.30 0.05 0.54% |
ASTELLAS PHARMA UNSPADR fundamentals help investors to digest information that contributes to ASTELLAS PHARMA's financial success or failures. It also enables traders to predict the movement of ASTELLAS Stock. The fundamental analysis module provides a way to measure ASTELLAS PHARMA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ASTELLAS PHARMA stock.
ASTELLAS |
ASTELLAS PHARMA UNSPADR Company Price To Earning Analysis
ASTELLAS PHARMA's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current ASTELLAS PHARMA Price To Earning | 28.51 X |
Most of ASTELLAS PHARMA's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ASTELLAS PHARMA UNSPADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, ASTELLAS PHARMA UNSPADR has a Price To Earning of 28.51 times. This is 10.33% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. This indicator is about the same for all Germany stocks average (which is currently at 28.72).
ASTELLAS PHARMA UNSPADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ASTELLAS PHARMA's current stock value. Our valuation model uses many indicators to compare ASTELLAS PHARMA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ASTELLAS PHARMA competition to find correlations between indicators driving ASTELLAS PHARMA's intrinsic value. More Info.ASTELLAS PHARMA UNSPADR is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers reporting about 0.65 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for ASTELLAS PHARMA UNSPADR is roughly 1.53 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ASTELLAS PHARMA's earnings, one of the primary drivers of an investment's value.ASTELLAS Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ASTELLAS PHARMA's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ASTELLAS PHARMA could also be used in its relative valuation, which is a method of valuing ASTELLAS PHARMA by comparing valuation metrics of similar companies.ASTELLAS PHARMA is currently under evaluation in price to earning category among its peers.
ASTELLAS Fundamentals
| Return On Equity | 0.0971 | |||
| Return On Asset | 0.0635 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.17 % | |||
| Shares Outstanding | 1.83 B | |||
| Price To Earning | 28.51 X | |||
| Revenue | 1.41 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 348.55 B | |||
| Net Income | 100.86 B | |||
| Cash And Equivalents | 305.99 B | |||
| Cash Per Share | 165.15 X | |||
| Total Debt | 308 M | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 905.03 X | |||
| Cash Flow From Operations | 325.33 B | |||
| Earnings Per Share | 0.57 X | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 24.49 B | |||
| Z Score | 47.4 | |||
| Annual Yield | 0.03 % | |||
| Last Dividend Paid | 55.0 |
About ASTELLAS PHARMA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ASTELLAS PHARMA UNSPADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ASTELLAS PHARMA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ASTELLAS PHARMA UNSPADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15455 people.
Currently Active Assets on Macroaxis
Other Information on Investing in ASTELLAS Stock
ASTELLAS PHARMA financial ratios help investors to determine whether ASTELLAS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ASTELLAS with respect to the benefits of owning ASTELLAS PHARMA security.